Relationship between the initial dose of micafungin and its efficacy in patients with candidemia

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of Infection and Chemotherapy

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/S10156-007-0522-YPMID 17721682
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Micafungin

  2012cited by this paper
• Association of Fluconazole Area under the Concentration-Time Curve/MIC and Dose/MIC Ratios with Mortality in Nonneutropenic Patients with Candidemia

  2006cited by this paper
• International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia

  2005cited by this paper
• Pharmacokinetic and Maximum Tolerated Dose Study of Micafungin in Combination with Fluconazole versus Fluconazole Alone for Prophylaxis of Fungal Infections in Adult Patients Undergoing a Bone Marrow or Peripheral Stem Cell Transplant

  2005cited by this paper
• A Multicenter, Open-Label Clinical Study of Micafungin (FK463) in the Treatment of Deep-seated Mycosis in Japan

  2004cited by this paper
• Successful treatment of oesophageal candidiasis by micafungin: a novel systemic antifungal agent

  2004cited by this paper
• Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation.

  2004cited by this paper
• A randomized, double-blind, parallel-group, dose-response study of micafungin compared with fluconazole for the treatment of esophageal candidiasis in HIV-positive patients.

  2004cited by this paper
• Antifungal agents: mechanisms of action.

  2003cited by this paper
• Caspofungin: the first in a new class of antifungal agents.

  2003cited by this paper
• A prospective observational study of candidemia: epidemiology, therapy, and influences on mortality in hospitalized adult and pediatric patients.

  2003cited by this paper
• Antifungal Susceptibility Survey of 2,000 Bloodstream Candida Isolates in the United States

  2003cited by this paper
• A randomized and blinded multicenter trial of high-dose fluconazole plus placebo versus fluconazole plus amphotericin B as therapy for candidemia and its consequences in nonneutropenic subjects.

  2003cited by this paper
• Epidemiology of Candida species infections in critically ill non-immunosuppressed patients.

  2003cited by this paper
• The echinocandin antifungals: an overview of the pharmacology, spectrum and clinical efficacy

  2003cited by this paper
• Echinocandin antifungal drugs.

  2003cited by this paper
• In vivo activity of micafungin in a persistently neutropenic murine model of disseminated infection caused by Candida tropicalis.

  2002cited by this paper
• Comparison of caspofungin and amphotericin B for invasive candidiasis.

  2002cited by this paper
• Secular Trends of Candidemia Over 12 Years in Adult Patients at a Tertiary Care Hospital

  2002cited by this paper
• Guidelines for the management of intravascular catheter-related infections.

  2001cited by this paper
• Compartmental Pharmacokinetics and Tissue Distribution of the Antifungal Echinocandin Lipopeptide Micafungin (FK463) in Rabbits

  2001cited by this paper
• Guidelines for the management of intravascular catheter-related infections.

  2001cited by this paper
• Hitting a new target with echinocandins. Why chase something else?

  2001cited by this paper
• In Vitro Activities of a New Lipopeptide Antifungal Agent, FK463, against a Variety of Clinically Important Fungi

  2000cited by this paper
• Predicting outcome among intensive care unit patients using computerised trend analysis of daily Apache II scores corrected for organ system failure

  1988cited by this paper
• National Committee for Clinical Laboratory Standards.

  1980cited by this paper

• Association of Doses Based on Body Constitutional Parameters with the Efficacy of Micafungin in Candidemia.

  2025cites this paper
• Assessment of micafungin loading dosage regimens against Candida spp. in ICU patients by Monte Carlo simulations

  2020cites this paper
• Nuevos antifúngicos, nuevas dianas y estrategias terapéuticas para el tratamiento de las micosis invasoras: revisión de la bibliografía (2005-2009)

  2020cites this paper
• Efficacy and safety of micafungin in unrelated cord blood transplant recipients

  2019cites this paper
• Echinocandin prophylaxis in patients undergoing haematopoietic cell transplantation and other treatments for haematological malignancies

  2018cites this paper
• PICO 2 . 0 project . Development of educational therapeutic ecommendations using the DELPHI technique on invasive candidiasis n critically ill adult patients in special situations

  2017cites this paper
• [Echinocandins: Applied pharmacology].

  2016cites this paper
• Safety and Efficacy of Intermittent Intravenous Administration of High-Dose Micafungin.

  2015cites this paper
• EPICO 2.0 PROJECT. Development of educational therapeutic recommendations using the DELPHI technique on invasive candidiasis in critically ill adult patients in special situations.

  2014cites this paper
• [Relationship between the effectiveness and dose of micafungin in the treatment of candidemia].

  2014cites this paper
• [Factors affecting the pharmacokinetics after living donor liver transplant].

  2012cites this paper
• Utilization Patterns of Caspofungin and Micafungin for Treatment of Invasive Fungal Infections

  2012cites this paper
• Addressing current medical needs in invasive fungal infection prevention and treatment with new antifungal agents, strategies and formulations

  2011cites this paper
• Effect of fluid loading during hypovolaemic shock on caspofungin pharmacokinetic parameters in pig

  2011cites this paper
• Echinocandin pharmacodynamics: review and clinical implications.

  2010cites this paper
• pharmacotherapy of Candida Infections with echinocandins

  2009cites this paper
• The impact of total bilirubin on plasma micafungin levels in living-donor liver transplantation recipients with severe liver dysfunction.

  2009cites this paper
• Prognostic factors for patients with culture-positive Candida infection undergoing abdominal surgery.

  2009cites this paper
• Novel antifungal agents, targets or therapeutic strategies for the treatment of invasive fungal diseases: a review of the literature (2005-2009).

  2009cites this paper
• Utilization and dosage pattern of echinocandins for treatment of fungal infections in US hospital practice*

  2009cites this paper
• Refractory neonatal candidemia and high-dose micafungin pharmacotherapy

  2009cites this paper
• In Vivo Pharmacodynamic Target Investigation for Micafungin against Candida albicans and C. glabrata in a Neutropenic Murine Candidiasis Model

  2008cites this paper